Clinical Trials Logo

Clinical Trial Summary

According to the 2022 ELN guidelines patients with high-risk acute myeloid leukemia were randomly divided into MA-BUCY2 conditioning group and BuCy2 conditioning group,to evaluate the efficacy and safety of two conditioning regimens in haploidentical hematopoietic stem cell transplantation.


Clinical Trial Description

High risk acute myeloid leukemia patients were randomly divided into two groups before conditioning of haploidentical hematopoietic stem cell transplantation.The control group will use the BUCY2 conditioning,and the experimental group will use mitoxantrone liposome combined with BUCY2 for conditioning. After transplantation,we will observe the difference of one year relapse rates between two goups,also the adverse reactions of conditioning,GVHD,OS and PFS of the patients in two groups also been observed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05814731
Study type Interventional
Source First Affiliated Hospital Xi'an Jiaotong University
Contact xiaonig wang, M.D.
Phone 0086-18991232608
Email wangxn99@163.com
Status Not yet recruiting
Phase N/A
Start date April 15, 2023
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04098653 - Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT Phase 2/Phase 3
Recruiting NCT03256071 - Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT Phase 2/Phase 3
Recruiting NCT04123392 - Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT Phase 2/Phase 3
Recruiting NCT03733327 - BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT Phase 2/Phase 3
Completed NCT05600725 - Novel Cardiac Pacing to Initiate Cardiac Remodeling in Heart Failure N/A
Not yet recruiting NCT06385808 - Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML N/A
Recruiting NCT03530085 - Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT Phase 2/Phase 3
Recruiting NCT03229616 - BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT Phase 2/Phase 3
Recruiting NCT05449899 - G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT Phase 2/Phase 3
Recruiting NCT05453552 - G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT Phase 2/Phase 3
Completed NCT02671708 - IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT Phase 2/Phase 3
Recruiting NCT03385096 - Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT Phase 2/Phase 3
Recruiting NCT04713956 - G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Phase 2/Phase 3
Completed NCT02744742 - G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Phase 2/Phase 3
Not yet recruiting NCT05814718 - Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT N/A